News
Benign MS is real in small minority of patients
But benign disease tracks poorly with disability measures and lacks agreement between patients and physicians.
We have updated our Privacy Policy. Please take the time to review
Article
Neurofilaments: A Biomarker of Long-Term Outcome in MS?
In patients with multiple sclerosis (MS), levels of light-chain neurofilament (NfL) in CSF at diagnosis seem to predict long-term clinical outcome...
Conference Coverage
Serum Nf-L shows promise as biomarker for BMT response in MS
An analysis of paired samples suggests a valuable role for serum Nf-L in predicting MS severity and treatment response.
Article
New MS Subtype Shows Absence of Cerebral White Matter Demyelination
A new subtype of multiple sclerosis (MS) called myelocortical MS is characterized by demyelination only in the spinal cord and cerebral cortex and...
Conference Coverage
Aspirin May Be an Effective Pretreatment for Exercise in Patients With MS
LOS ANGELES>—Aspirin may be an effective pretreatment for exercise in patients with multiple sclerosis (MS), according to a study described at...
News
Treatment of relapsing progressive MS may reduce disability progression
A subset of MS patients with inflammatory relapse showed less risk of progression with disease-modifying therapy.
Conference Coverage
A Rational Approach to Starting, Stopping, and Switching DMTs
NASHVILLE—What guides decisions to start, stop, switch, or restart disease-modifying therapy (DMT) in patients with multiple sclerosis (MS)—...
Conference Coverage
Fitbit Flex is feasible, provides nuanced step count data in MS patients
Article
Investigators Describe the MS Prodrome
The prodrome of multiple sclerosis (MS) may include an increased risk of nervous system, sensory, and musculoskeletal disorders, according to...
Conference Coverage
Lipid Metabolism May Be a Therapeutic Target in MS
NASHVILLE—Multiple sclerosis (MS) traditionally has been considered a chronic inflammatory autoimmune disease, but inflammation decreases as the...
Conference Coverage
Ozanimod May Provide Better MS Outcomes Than Interferon Beta
NASHVILLE—Two doses of ozanimod provide greater benefits on annualized relapse rate and MRI end points than interferon beta-1a...
Conference Coverage
CMSC Guideline Re-Examines Use of Gadolinium-Based Contrast Agents
NASHVILLE—Gadolinium-based contrast agents (GBCAs) are necessary for the accurate initial diagnosis of patients experiencing a...
Conference Coverage
Eating Fish May Be Associated With a Reduced Risk of MS
LOS ANGELES—Eating fish at least once per week or eating fish one to three times per month, in addition to taking daily fish oil...
Conference Coverage
High-Intensity Interval Exercise May Be Appropriate for Patients With MS
NASHVILLE—For patients with multiple sclerosis (MS) and walking impairments, high-intensity interval exercise is as enjoyable as...
Conference Coverage
-
-
-
-
-
Multimedia
Question 1 of 5